


FORM PTO-1449 (REV. 2-82)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Atty. Docket No. 1103326-0623	Serial No. 09/581,959
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: Lindfors et al.	
		Filing Date: June 19, 2000	Group:



UNITED STATES PATENT DOCUMENTS

*Examiner Initial	Document No.							Date	Name	Class	Sub-Class	Filing Date, if Appropriate
Z. F	5	2	9	6	4	7	5	03/22/1994	Flesch et al.	514	108	
E. F	5	3	4	4	8	2	5	09/06/1994	Khanna et al.	514	108	
Z. F	5	6	5	0	1	6	8	07/22/1997	Preis et al.	424	465	

UNITED STATES PATENT APPLICATIONS

*Examiner Initial	Document No.							Date	Name	Class	Sub-Class	Filing Date, if Appropriate
Z. F		1	7	1	9	5	0		Ungell			10/29/1998

FOREIGN PATENT DOCUMENTS

*Examiner Initial	Document No.							Date	Country	Class	Sub-Class	Translation Yes No	
Z. F	9	9	1	8	9	7	2	04/22/1999	WO				
Z. F	8	8	0	0	8	2	9	02/11/1988	WO				
Z. F	9	7	0	5	9	0	3	02/20/1997	WO				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

Z. F		Sato et al., Alendronate Localization in Rat Bone and Effects on Osteoclast Ultrastructure. <u>J. Clin. Invest.</u> 88, 2095-2105, 1991.
Z. F		Lin, J. H. Bisphosphonates: A Review of Their Pharmacokinetic Properties. <u>Bone</u> 18, 75-85, 1996.

Examiner:

Zohar F.

Date Considered:

6/14/02

*Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED


TECH CENTER 1600/2900

JAN 04 2002

Page 2 of 4

FORM PTO-1449 (REV. 2-82)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Atty. Docket No. 1103326-0623	Serial No. 09/581,939
		Applicant: Lindfors et al.	
		Filing Date: June 19, 2000	Group:

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT



UNITED STATES PATENT DOCUMENTS

*Examiner Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date, if Appropriate

FOREIGN PATENT DOCUMENTS

*Examiner Initial	Document No.	Date	Country	Class	Sub-Class	Translation Yes No
Z. f.	9 8 5 2 5 4 7	11/26/1998	WO			
Z. f.	9 9 1 5 1 5 5	04/01/1999	WO			
Z. f.	9 6 3 8 1 5 6	12/05/1996	WO			
Z. f.	9 3 2 1 9 0 7	11/11/1993	WO			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

Z. f.	/	Fleisch, H. Bisphosphonates in Bone Disease. <u>Stampli & Co.</u> , Bern 1993, p. 50 .
Z. f.	/	Gertz et al. Studies of the Oral Bioavailability of Alendronate. <u>Clinical Pharmacology & Therapeutics</u> , Vol. 58, pp. 288-298, 1995.
Z. f.		Aulton M. E. Pharmaceutics- The Science of Dosage Form Design, <u>Churchill Livingstone</u> 1988, Hong Kong.
Z. f.	/	Charman et al. Physicochemical and Physiological Mechanisms for the Effects of Food on Drug Absorption: The Role of Lipids and pH. <u>J. Pharm. Res.</u> 86 (3): 269-282, 1997.
Z. f.	/	Hoogdalem et al., Intestinal Drug Absorption Enhancement: An Overview. <u>Pharm. Theor</u> Vol. 44, 407-443, 1989.

Examiner: *Zahr Fug* Date Considered: *6/14/02*

*Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


RECEIVED

JAN 04 2002

TECH CENTER 1600/2900

Page 3

FORM PTO-1449 (REV. 2-82)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Atty. Docket No. 1103326-0623	Serial No. 09/581,966
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: Lindfors et al.	
		Filing Date: June 19, 2000	Group:



UNITED STATES PATENT DOCUMENTS

*Examiner Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date, if Appropriate

FOREIGN PATENT DOCUMENTS

*Examiner Initial	Document No.	Date	Country	Class	Sub-Class	Translation Yes No

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

2.F	1	Muranishi et al., Absorption Enhancers. <u>Crit. Rev Ther Drug Carrier Syst</u> Vol. 7, 1-33, 1990.
2.F	-	Swenson et al., Intestinal Permeability Enhancement. <u>Adv. Drug Deliv Rev.</u> Vol. 8, 39-92, 1998.
2.F		de Boer ABG (Ed.), Drug Absorption Enhancement. <u>Harwood Academic Publishers</u> , 1994.
2.F	1	Baughman et al., Oral Delivery of Anticoagulant Doses of Heparin. <u>Circulation</u> 98 (16): 1610-1615, 1998.
2.F		Bai et al., Targeting of Peptide and Protein Drugs to Specific Sites in the Oral Route. <u>Crit. Rev. Therap. Drug Carrier Syst.</u> 12 (4): 339-371, 1995.
2.F		Dowty et al, <u>Pharm. Sci. Suppl.</u> , Vol 1, No. 1:448, 1998, ABSTRACT, 1998 AAPS Meeting in San Francisco.

Examiner:

Zobuh Fay


Date Considered:

6/14/02

*Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(REV. 2-82)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEAtty. Docket No.
1103326-0623Serial No.
09/581,959INFORMATION DISCLOSURE STATEMENT
BY APPLICANTApplicant:
Lindfors et al.Filing Date:
June 19, 2000

Group:



UNITED STATES PATENT DOCUMENTS

*Examiner Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date, if Appropriate

FOREIGN PATENT DOCUMENTS

*Examiner Initial	Document No.	Date	Country	Class	Sub-Class	Translation Yes No

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

Z. F	Bowe et al., Design of Compounds that Increase the Absorption of Polar Molecules. <u>Proc. Nat. Acad. Sci.</u> 94 (22): 12218-23, 1997.
Z. F	Chao et al., Enhancement of Intestinal Model Compound Transport by DS-1, a Modified Quillaja Saponin. <u>J. Pharm. Sci</u> 87 (11): 1395-1399, 1998.
Z. F	Chao et al., Molecular Weight-Dependent Paracellular Transport of Fluorescent Model Compounds Induced by Palmitoylcarnitine Chloride across the Human Intestinal Epithelial Cell Line Caco-2. <u>J. Drug Targeting</u> 6(1): 37-43, 1998.
Z. F	Fix J. A., Strategies for Delivery of Peptides Utilizing Absorption-Enhancing Agents. <u>J. Pharm. Sci.</u> 85(12): 1282-1285, 1996.

Examiner:

Zohrab Foy

Date Considered:

6/14/02

*Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.